机译:TCT-167在医院的杂交方法中使用经皮冠状动脉干预的慢性总闭塞:从进展-CTO的更新(预期全球登记处为慢性总遮挡干预的研究)国际登记处
Minneapolis Heart Institute Abbott Northwestern Hospital University of Szeged;
Division of Cardiology Department of Medicine Columbia University Medical Center New York;
Henry Ford Hospital;
Henry Ford Hospital;
Henry Ford Hospital;
Henry Ford Hospital;
Massachusetts General Hospital;
Beth Israel Deaconess Medical Center;
UCSD;
UCSD;
UCSD;
Baylor Heart and Vascular Hospital;
Baylor Heart and Vascular Hospital;
UPMC;
Biomedical Research Foundation/Central Arkansas Veterans Healthcare System;
Central Arkansas VA Healthcare System;
E.N. Meshalkin National Medical Research Center Ministry of Health Care of Russian Federation;
Baylor Research Institute The Heart Hospital Baylor Plano;
The Heart Hospital Baylor Plano;
Minneapolis VA Healthcare System;
Hellenic Red Cross General Hospital of Athens;
Hellenic Red Cross General Hospital of Athens;
Hellenic Red Cross General Hospital of Athens;
Emory University;
Minneapolis Heart Institute;
UT Southwestern Medical Center/ VA North Texas Health Care System;
机译:TCT-167在医院的杂交方法中使用经皮冠状动脉干预的慢性总闭塞:从进展-CTO的更新(预期全球登记处为慢性总遮挡干预的研究)国际登记处
机译:慢性总闭塞的医院结果经皮冠状动脉干预患者患者患者从国际多中心慢性总阻塞登记处的患者患有先前的冠状动脉旁路接枝洞察力
机译:用于预测慢性完全阻塞性经皮冠状动脉介入治疗技术成功率的新型评分系统的开发和验证PROGRESS CTO(慢性完全阻塞性介入研究的潜在全球注册机构)评分
机译:Xransradial冠状动脉干预慢性总闭塞
机译:MR引导的慢性总闭塞经皮血运重建方法的发展。
机译:预测总慢性经皮冠状动脉介入治疗期间围手术期并发症的评分系统的开发和验证:慢性完全阻断干预(PROGRESS CTO)并发症评分研究的前瞻性全球注册机构
机译:用于预测慢性完全阻塞性经皮冠状动脉介入治疗技术成功的新型评分系统的开发和验证PROGRESS CTO(研究慢性完全阻塞性介入治疗的潜在全球注册机构)评分